Abstracts tagged "Response Criteria"

Abstract Number: 1515 • ACR Convergence 2020
Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort
Philip Carlucci¹, Andrea Fava², Kristina Deonaraine¹, Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Poor therapeutic response rates contribute to the increased morbidity and mortality associated with lupus nephritis. Early identification of patients likely to respond is crucial…
Abstract Number: 1516 • ACR Convergence 2020
The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership
Philip Carlucci¹, Kristina Deonaraine¹, Andrea Fava², Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…
Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Corinne Miceli-Richard¹, Denis Poddubnyy², Atul Deodhar³, Weibin Bao⁴, Craig Parman⁵, Brian Porter⁶ and Effie Pournara⁵, ¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharmaceuticals Corporation, East Hannover, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Augusta Ortolan¹, Victoria Navarro-Compán², Alexandre Sepriano³, Robert Landewé⁴, Désirée van der Heijde⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center, Padova, Italy, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Leiden University Medical Center, Portela Loures, Portugal, ⁴Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
Abstract Number: 0200 • ACR Convergence 2020
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study
Kunihiro Yamaoka¹, Stanley B Cohen², Naonobu Sugiyama³, Harry Shi⁴, Jose L Rivas⁵, Annette Diehl⁴ and Josef Smolen⁶, ¹Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ²Metroplex Clinical Research Center, Dallas, TX, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer SLU, Madrid, Spain, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…
Abstract Number: 0427 • ACR Convergence 2020
Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis
Emily Rose¹, Marcela Ferrada¹, Kaitlin Quinn², Wendy Goodspeed¹, Laurent Arnaud³ and Peter C. Grayson⁴, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, BETHESDA, MD, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ³Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, ⁴Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disorder of cartilage that lacks validated disease activity measures. Physician global assessment (PhGA) is a measure…
Abstract Number: 0480 • ACR Convergence 2020
Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
Julia Dupont¹, Gregory Guernec², Yannick Degboé³, Frédéric Lioté⁴, Olivier Vittecoq⁵, Arnaud Constantin⁶ and Adeline Ruyssen Witrand⁷, ¹University Hospital of Thoulouse, Toulouse, ²Inserm UMR 1027, TOULOUSE CEDEX 9, France, ³University Hospital of Toulouse, Toulouse, ⁴AP-HP, Paris, France, ⁵University Hospital of Rouen, Rouen, France, ⁶Rheumatology Department, Toulouse University Hospital, Toulouse, France, ⁷Rheumatology center, University Hospital of Toulouse, Inserm 1027, University Paul Sabatier, Toulouse, France, Toulouse, France
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…
Abstract Number: 0482 • ACR Convergence 2020
Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Edward C Keystone¹, Mohammad Movahedi², Angela Cesta³, Claire Bombardier⁴, John Sampalis⁵ and Emmanouil Rampakakis⁵, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, ON, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada, ⁵JSS Medical Research, St-Laurent, QC, Canada
Background/Purpose: Treat-to-target recommendations for rheumatoid arthritis (RA) dictate that remission or low disease activity should be aimed. Although numerous composite indices are available, the clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].